Clinical trial
A Safety Study of EPC2407, A Anti-Cancer Drug With Vascular Disrupting Activity…
NCT00423410 · EpiCept Corporation, Industry · Completed
Key facts
| NCT number | NCT00423410 |
|---|---|
| Title | A Safety Study of EPC2407, A Anti-Cancer Drug With Vascular Disrupting Activity: In Patients With Advanced Cancer |
| Official title | A First In Man Phase I Study Of EPC2407, A Microtubule Inhibitor Anti-Cancer Drug With Tumor Vascular Endothelial Disrupting Activity: Intravenous Administration Daily For Three Days In Patients With Advanced Solid Tumors And Lymphomas |
| Lead sponsor | EpiCept Corporation, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Advanced Cancer |
| Intervention type | Drug |
| Interventions | EPC2407 (crinobulin) |
| Enrollment | 30 |
| Start date | Dec 1, 2006 |
| Primary completion | Apr 1, 2009 |
| Completion | Sep 1, 2009 |
| First posted | Jan 18, 2007 |
| Last update posted | Sep 10, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: